Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $9.40 Average Target Price from Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has received an average rating of “Hold” from the five research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $9.40.

A number of brokerages have weighed in on RXRX. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 26th. Bank of America cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $3.50 on Tuesday. Recursion Pharmaceuticals has a 1 year low of $2.80 and a 1 year high of $7.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50. The company’s 50-day moving average is $3.41 and its 200 day moving average is $4.28. The stock has a market capitalization of $1.85 billion, a P/E ratio of -2.36 and a beta of 1.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $24.56 million. During the same quarter in the previous year, the company earned ($0.53) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 671.7% on a year-over-year basis. On average, sell-side analysts expect that Recursion Pharmaceuticals will post -0.93 earnings per share for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CFO Ben R. Taylor sold 7,956 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the sale, the chief financial officer owned 1,180,318 shares in the company, valued at approximately $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $3.10, for a total transaction of $93,000.00. Following the completion of the sale, the director owned 6,229,863 shares in the company, valued at approximately $19,312,575.30. This trade represents a 0.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 299,680 shares of company stock worth $1,180,121. 8.43% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 1.7% in the third quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock worth $163,702,000 after buying an additional 556,868 shares in the last quarter. Bank Pictet & Cie Europe AG bought a new position in shares of Recursion Pharmaceuticals in the third quarter worth approximately $7,954,000. Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 10.3% in the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after buying an additional 3,708,975 shares in the last quarter. Rafferty Asset Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 110.6% in the third quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock worth $3,661,000 after buying an additional 394,022 shares in the last quarter. Finally, DNB Asset Management AS bought a new position in shares of Recursion Pharmaceuticals in the third quarter worth approximately $1,531,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.